The company's treatment for hereditary angioedema reduced attacks by 87% vs. placebo in a Phase 3 trial, clearing the way for ...

With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for ...

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...

The gene editing treatment targets the relatively common 1717-1G>A splicing mutation, which does not respond to many current ...

Scientists have taken an important step toward a gene therapy that could one day turn off the extra genetic material that ...

We'll know more about the company's medium-term prospects by the end of the year.

Scientists have unveiled a CRISPR-based tool, ThermoCas9, capable of pinpointing and removing tumor DNA by detecting cancer-specific chemical markers, potentially sparing healthy cells. In parallel, ...

Scientists are laying the groundwork for treating one of the most common genetic conditions in humans. Research out today highlights a promising new approach to Down syndrome, also known as trisomy 21 ...

Rice University scientists used advanced CRISPR techniques to study PEX11, a protein coded by five genes in Arabidopsis plants, revealing its role in controlling peroxisome growth during the ...

Crispr Therapeutics AG's partnership with Vertex Pharmaceuticals offers financial support, mentorship, and validation, enhancing Crispr's approach and technology. Despite slower-than-expected Casgevy ...